MicroRNA‐181a promotes docetaxel resistance in prostate cancer cells
Abstract
Docetaxel is one of the primary drugs used for treating castration resistant prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to docetaxel therapy and their disease will continue to progress. The mechanisms by which resistance develops are still incompletely understood. This study seeks to determine the involvement of miRNAs, specifically miR‐181a, in docetaxel resistance in CRPC.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2017
- Source ID
- 10.1002/pros.23358
Entities
People
- Alan P. Lombard
- Allen C Gao
- Cameron M. Armstrong
- Chengfei Liu
- Christopher P Evans
- Wei Lou
Organizations
- Biomedical Laboratory Research and Development, VA Office of Research and Development
- Center for Scientific Review
- United States Army Medical Command
- University of California, Davis
- VA Northern California Health Care System